Amgen PCSK9 drug passes safety test

Share this article:

Amgen issued new results late yesterday from its Phase II OSLER safety trial of LDL-cholesterol lowerer and PCSK9 inhibitor evolocumab (AMG-145). The drug was "not associated with a major increase in adverse events versus standard of care (SOC)," the company said in a statement.

Findings show AEs occurred in 81.4% of patients taking evolocumab compared with 73.1% in SOC. Serious AEs surfaced in 7.1% of patients on the PCSK9 inhibitor as opposed to 6.3% in SOC.

Evolocumab's efficacy was also in line with previous reports. Mean LDL-C reductions were 52%. Previous results  have shown evolomcumab's ability to lower levels by up to 59%. Amgen expects to report outcomes data from its FOURIER trial on the treatment in 2017.

Credit Suisse expects evolucumab to launch in 2016 and reach sales of $1 billion by 2020. ISI Group analyst Mark Schoenebaum estimated sales reaching the blockbuster mark by 2018.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.